Palisade Bio, Inc. (PALI)
- Previous Close
6.35 - Open
6.10 - Bid 6.09 x 200
- Ask 6.28 x 200
- Day's Range
5.72 - 6.40 - 52 Week Range
3.82 - 36.60 - Volume
70,139 - Avg. Volume
1,076,044 - Market Cap (intraday)
5.406M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-26.49 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.75
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
www.palisadebio.comRecent News: PALI
Performance Overview: PALI
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PALI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PALI
Valuation Measures
Market Cap
5.30M
Enterprise Value
-6.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.36
Price/Book (mrq)
0.47
Enterprise Value/Revenue
-27.03
Enterprise Value/EBITDA
0.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.85%
Return on Equity (ttm)
-103.40%
Revenue (ttm)
250k
Net Income Avi to Common (ttm)
-12.32M
Diluted EPS (ttm)
-26.49
Balance Sheet and Cash Flow
Total Cash (mrq)
12.43M
Total Debt/Equity (mrq)
3.26%
Levered Free Cash Flow (ttm)
-6.47M
Research Analysis: PALI
Company Insights: PALI
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: PALI
Daily – Vickers Top Insider Picks for 11/26/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 11/24/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 11/23/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 11/22/2021
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.